19,467 Shares in Silence Therapeutics plc (NASDAQ:SLN) Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Silence Therapeutics plc (NASDAQ:SLN) during the 4th quarter, Holdings Channel reports. The fund bought 19,467 shares of the company’s stock, valued at approximately $134,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SLN. GAMMA Investing LLC grew its holdings in shares of Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Silence Therapeutics during the fourth quarter worth about $69,000. FNY Investment Advisers LLC bought a new position in Silence Therapeutics during the fourth quarter worth about $120,000. Verition Fund Management LLC acquired a new position in Silence Therapeutics in the third quarter valued at about $207,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Silence Therapeutics in the third quarter worth about $318,000. Institutional investors own 98.73% of the company’s stock.

Analyst Ratings Changes

SLN has been the topic of several recent analyst reports. Chardan Capital reiterated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. The Goldman Sachs Group cut their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley lowered their price objective on shares of Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. BMO Capital Markets cut their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, Silence Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Trading Up 11.1 %

Shares of SLN opened at $3.69 on Friday. The stock has a market capitalization of $110.44 million, a price-to-earnings ratio of -2.35 and a beta of 1.08. Silence Therapeutics plc has a 12 month low of $3.19 and a 12 month high of $24.38. The firm has a fifty day simple moving average of $4.68 and a 200 day simple moving average of $10.02.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.